White Paper

The Future Of ADC Manufacturing: Benefits Of Single-Use Isolators For Cytotoxic Payload Handling

Source: ILC Dover

By Scott Patterson, Consulting SME for Pharma Containment and Powder Handling

ILC_SUS_ Isolator

High-potency cytotoxic payloads are vital for anti-cancer Antibody-Drug Conjugates (ADCs), and currently most ADC production is outsourced to CDMOs. It's important for drug research and development parties to prioritize containment controls for regulatory compliance, mitigating the potential exposure risks and reducing cross-contamination risk. ADCs face a high failure rate in clinical trials due to design complexity, payload toxicity, and other factors.

Enhance your ADC manufacturing processes by leveraging the performances and inherent benefits of single-use isolators, including:

  • High-Containment Performance
  • Flexibility & Process Simplification
  • Economic Benefits
  • And Sustainability
access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online